For those who missed the #Novacyt AGM here are some highlights 😊...
2021 Guidance
#Novacyt Small bolt on M&A can be financed from cash
Little reminder IT-IS purchase cost just £10m
Listing plans (AIM, EuroNext, NASDAQ)
"As of today we have no plans to change our listings"
#Novacyt
#Novacyt Midcap plans (£1b >£2b)
Currently working on USA expansion plans, #Novacyt will update market in near future
🇺🇲 Is largest global diagnostics market
37% AIM v 63% EuroNext #Novacyt
#Novacyt have so far do donated 200,000 Genesig tests of 1m to #UNICEF which have not come from excess inventory
Largest #Novacyt growth potential, Point of Care/Near Patient testing 🔬
(q16/q32's/ProMATE)
#Novacyt outlook for COVID testing in the coming years
#Novacyt auditor treatment of DHSC accounting
#Novacyt mainland market strategy will focus on Direct sales
#Novacyt CEO Graham Mullis retirement message as he hands over the keys to David Almond
Congratulations to Graham for years of hard work & vision enabling @NovacytGroup to respond to the pandemic, achieve profitability & setting the company on the path to mid cap status 💫🌟💫
#Novacyt Chairman of the Board James Wakefield thanks Graham for his past endevors & welcomes new CEO David Almond to the business, highlighting his can-do attitude, leadership, commercial experience & recent success with prior companies dual listing on NASDAQ
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.